Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, Japan, May 13, 2013 – Astellas Pharma Inc. (Tokyo: 4503; President and CEO: Yoshihiko Hatanaka, hereinafter called “the Company”) announced that at the meeting of the Board of...
Tokyo, May 8, 2013 – Astellas Pharma Inc. (Astellas; Tokyo: 4503) today announced its selection results based on a3 (a-cube), a website (http://www.astellas.com/jp/a-cube/) launched on May 17,...
TOKYO, JAPAN and BRIDGEWATER, N.J., May 7, 2013 – Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) and Drais Pharmaceuticals, Inc. (“Drais”) today announced that they have entered into a...
CAMBRIDGE, Mass. and TOKYO, Japan, May 2, 2013 - AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today reported that the U.S. Food and Drug Administration’s (FDA) Oncologic...
Chertsey, England and San Francisco, CA; 26 April, 2013: Today, Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. (Nasdaq:...
TOKYO, April 15, 2013 - Astellas Pharma Inc. (“Astellas”; Tokyo: 4503) today announced that Songlin Xue, M.D., Ph.D. has been named head of Global Pharmacovigilance (GPV). Dr. Xue will be...
TOKYO, April 10, 2013 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503) announced today that its collaborative research project with Johns HopkinsUniversity School of Medicine (“JHU”;...
TOKYO and SAN DIEGO, April 4, 2013 – Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today entered into a collaboration with Ambrx Inc. (“Ambrx”) for the discovery and development of...
San Francisco, CA and Tokyo, Japan – April 1, 2013 – Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that the companies have established an updated interim...
Tokyo, March 25, 2013 - Zeria Pharmaceutical Co., Ltd. (Tokyo: 4559; “Zeria”) and Astellas Pharma Inc. (Tokyo: 4503; “Astellas”) announced today that as of March 25, Zeria has obtained the...
Tokyo, March 18, 2013 – Astellas Pharma Inc. (Headquarters: Tokyo, President and CEO: Yoshihiko Hatanaka, hereinafter called “the Company”) announced that it completed acquisition of its own...
Tokyo, Japan, 7 March, 2013 – Astellas Pharma Inc. (“Astellas”;Tokyo:4503; President and CEO: Yoshihiko Hatanaka) and UCB Japan (“UCB Japan”: Tokyo, Japan, President and Representative...
CAMBRIDGE, Mass. and TOKYO, Japan, February 12, 2013 - AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced overall survival (OS) for tivozanib, an investigational...
Astellas Pharma Europe Ltd., Chertsey, UK, 11th January 2013. A new treatment, BETMIGATM (mirabegron) has received approval from the European Commission (EC) for the treatment of overactive...
Tokyo, Japan and Brussels, Belgium, 25th December, 2012 – Astellas Pharma Inc. (“Astellas”;Tokyo:4503; President and CEO: Yoshihiko Hatanaka) and UCB S.A. (“UCB"; Brussels, Belgium, CEO:...
Tokyo, Japan, December 21, 2012 – Nippon Boehringer Ingelheim Co., Ltd. (Headquarters: Shinagawa-ku, Tokyo; President: Yoshiaki Aono; hereinafter “NBI”) and Astellas Pharma Inc. (Tokyo:4503,...
CAMBRIDGE, Mass. and TOKYO, Japan, December 3, 2012 - AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the initiation of patient enrollment in a randomized,...
CAMBRIDGE, Mass. and TOKYO, Japan, November 28, 2012 -- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.S. Food and Drug Administration (FDA) has...
Tokyo, 15 November, 2012 –Astellas Pharma Inc. (Tokyo: 4503, ”Astellas”) announced today that it received a notice from AstraZeneca not to exercise an exclusive option to acquire the Phase...
CAMBRIDGE, Mass. and TOKYO, Japan, October 1, 2012 - AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced new data from the Phase 3 TIVO-1 trial (TIvozanib Versus...
CAMBRIDGE, Mass. and TOKYO, Japan, September 28, 2012 -- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that AVEO has submitted a New Drug Application (NDA) to...
Tokyo, Japan, September 26, 2012 - Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced that it has been selected for the second consecutive year in the Dow Jones Sustainability Asia Pacific...
Tokyo, Japan, September 20, 2012 –The High Energy Accelerator Research Organization (KEK) and Astellas Pharma Inc. (Tokyo:4503,“Astellas”) have today concluded an agreement to begin...
Tokyo, September 6, 2012 - Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced the donation of three high-standard ambulances to local municipalities in Japan. As part of the company’s...
Tokyo, Japan, August 10, 2012 – Astellas Pharma Inc. (“Astellas”, headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka) and AstraZeneca K.K. (“AstraZeneca”, headquarters: Osaka;...
Tokyo, August 8, 2012 - Astellas Pharma Inc. (“Astellas Pharma”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) today announced that it submitted an application for market authorization...
Tokyo, August 6, 2012 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced that it decided to close Urogenix, Inc. (“Urogenix”, Durham, NC,...
Tokyo, July 30, 2012 – Astellas Pharma Inc. (“Astellas,” Tokyo: 4503) today announced that it will hold its annual “Changing Tomorrow Day” (CT Day), an event in which Astellas Group...
Tokyo, Japan, July 30, 2012 – Tokyo Institute of Technology (“Tokyo-Tech”) and Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced on July 30 that they have signed a joint research...
A newly established international public-private partnership (PPP) between TI Pharma, Merck KGaA (Darmstadt, Germany), Astellas Pharma Inc. and the Swiss Tropical and Public Health Institute...
Follow us
